APA (7th ed.) Citation

DH, A., NJ, P., M, L., ZY, Z., X, N., T, W., & S, Y. (2025). Real-world clinical outcomes of cabozantinib as a second-line treatment for advanced hepatocellular carcinoma: A retrospective US claims analysis. The oncologist, 30(9), . https://doi.org/10.1093/oncolo/oyaf252

Chicago Style (17th ed.) Citation

DH, Ahn, Park NJ, Locker M, Zhou ZY, Nie X, Wang T, and Yu S. "Real-world Clinical Outcomes of Cabozantinib as a Second-line Treatment for Advanced Hepatocellular Carcinoma: A Retrospective US Claims Analysis." The Oncologist 30, no. 9 (2025). https://doi.org/10.1093/oncolo/oyaf252.

MLA (9th ed.) Citation

DH, Ahn, et al. "Real-world Clinical Outcomes of Cabozantinib as a Second-line Treatment for Advanced Hepatocellular Carcinoma: A Retrospective US Claims Analysis." The Oncologist, vol. 30, no. 9, 2025, https://doi.org/10.1093/oncolo/oyaf252.